The Wall Street Journal lambasted the Trump Administration's recent reclassification of marijuana as a Schedule III drug under the Controlled Substances Act, warning the move carries significant implications for public health, particularly regarding adolescent brain development.
The practical consequences are substantial, the newspaper's editorial board warned. The reclassification will allow marijuana growers and retailers to deduct business expenses from taxes, legitimizing the industry while simultaneously signaling government approval for a substance documented to harm developing brains.
"The pot lobby and its friends in state governments have insisted legalization wouldn’t increase teen use, but that’s proven to be false, like so many of their claims," the editorial board wrote.
A University of California, San Diego, study of 11,000 adolescents found that cannabis users experienced measurable impairment in brain development compared to non-users, including deficits in verbal recall, processing speed, inhibition control, working memory and spatial skills, the Journal noted. Researchers controlled for socio-demographics, family substance use history, prenatal exposure, and other drug use, eliminating confounding variables.
The findings are particularly troubling because adolescent pot users initially performed comparably to non-users on cognitive measures, the editors warned. However, as usage increased over time, their cognitive development plateaued while their peers continued improving. Study author Natasha Wade noted these seemingly modest differences can substantially impact learning, memory, and daily functioning.
Legalization advocates have repeatedly claimed that expanding access would not increase teen use, yet evidence contradicts this assertion, the board argued. A Journal of the American Medical Association study found adolescent cannabis use increased 38 percent following California's 2016 legalization referendum for recreational use — declining only during pandemic lockdowns.
Currently, 24 states permit recreational marijuana while 40 authorize medical use. The reclassification applies specifically to licensed medical marijuana producers and retailers, who will inevitably market products emphasizing therapeutic benefits despite mounting evidence of developmental risks.
Growing parental awareness of cannabis-associated dangers — including increased mental illness and cardiac problems — represents progress, the editorial board argued, adding that the administration's reclassification move undermines public health messaging and perpetuates the harmful misconception that marijuana poses minimal risk to developing adolescent brains.